Page 117 - 80 guidelines for the treatment of malaria_opt

ANNEX 3. Pharmacology of antimalarial medicines

a3.16 references
1. Krugliak M, Ginsburg H. Studies on the antimalarial mode of action of quinoline-
containing drugs: time-dependence and irreversibility of drug action, and interactions
with compounds that alter the function of the parasite’s food vacuole. Life Sciences, 1991,
49:1213–1219.
2. Bray PG et al. Access to hematin: the basis of chloroquine resistance. Molecular
Pharmacology, 1998, 54:170–179.
3. Gustafsson LL et al. Disposition of chloroquine in man after single intravenous and oral
doses. British Journal of Clinical Pharmacology, 1983, 15:471–479. A3
4. Walker O et al. Plasma chloroquine and desethylchloroquine concentrations in children
during and after chloroquine treatment for malaria. British Journal of Clinical Pharmacology,
1983:16:701–705.
5. White NJ et al. Chloroquine treatment of severe malaria in children. Pharmacokinetics,
toxicity, and new dosage recommendations. New England Journal of Medicine, 1988,
319:1493–1500.
6. Mnyika KS, Kihamia CM. Chloroquine-induced pruritus: its impact on chloroquine
utilization in malaria control in Dar es Salaam. Journal of Tropical Medicine and Hygiene,
1991, 94:27–31.
7. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Safety, 2004, 27:25–61.
8. Riou B et al. Treatment of severe chloroquine poisoning. New England Journal of Medicine,
1988, 318:1–6.
9. Clemessy JL et al. Treatment of acute chloroquine poisoning: a 5-year experience. Critical
Care Medicine, 1996, 24:1189–1195.
10. Winstanley PA et al. The disposition of amodiaquine in Zambians and Nigerians with
malaria. British Journal of Clinical Pharmacology, 1990, 29:695–701.
11. Hatton CS et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis
against malaria. Lancet, 1986, 1:411–414.
12. Miller KD et al. Severe cutaneous reactions among American travelers using pyrimethamine-
sulfadoxine (Fansidar) for malaria prophylaxis. American Journal of Tropical Medicine and
Hygiene, 1986, 35:451–458.
13. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria
chemotherapy. Bulletin of the World Health Organization, 1991, 69:297–304.
14. Winstanley PA et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine
in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.
British Journal of Clinical Pharmacology, 1992, 33:143–148.
15. Price R et al. Pharmacokinetics of mefloquine combined with artesunate in children with
acute falciparum malaria. Antimicrobial Agents and Chemotherapy, 1999, 43:341–346.
16. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical
implications. Clinical Pharmacokinetics, 1996, 30:263–299
17. Simpson JA et al. Population pharmacokinetics of mefloquine in patients with acute
falciparum malaria. Clinical Pharmacology and Therapeutics, 1999, 66:472–484.

103